{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T17:35:51Z","timestamp":1793900151843,"version":"4.8.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T00:00:00Z","timestamp":1681862400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Strongbridge Biopharma plc, a wholly-owned subsidiary of Xeris Biopharma Holdings, Inc."}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pituitary"],"published-print":{"date-parts":[[2023,8]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Endogenous Cushing\u2019s syndrome (CS) is a rare endocrine condition caused by chronic oversecretion of cortisol, resulting in a diverse constellation of symptoms. This study examined the ongoing burden of illness (BOI), from the first appearance of symptoms through treatment, which is currently not well evaluated.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A quantitative, cross-sectional, web-enabled survey including 5 validated patient reported outcomes (PRO) measures was conducted in patients with CS who had been diagnosed\u2009\u2265\u20096 months prior and who had received\u2009\u2265\u20091 treatment for their endogenous CS at the time of the survey.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Fifty-five patients participated in this study; 85% were women. The mean age was 43.4\u2009\u00b1\u200912.3 years (\u00b1\u2009standard deviation, SD). On average, respondents reported a 10-year gap between the first occurrence of symptoms and diagnosis; 80% underwent surgical treatment for CS. Respondents experienced symptoms on 16 days in a typical month, and their health-related quality of life was moderately impacted based on the CushingQoL score. Weight gain, muscle fatigue, and weakness were the most common symptoms and 69% percent of patients reported moderate or severe fatigue using the Brief Fatigue Inventory. Following treatment, the occurrence of most symptoms declined over time, although anxiety and pain did not significantly decrease. Overall, 38% of participants reported an annual average of 25 missed workdays due to CS symptoms.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>These results demonstrate a BOI in CS despite ongoing treatment and illustrate the need for interventions to address persistent symptoms, particularly weight gain, pain, and anxiety.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11102-023-01314-7","type":"journal-article","created":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T07:03:14Z","timestamp":1681887794000},"page":"364-374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Evaluating the burden of endogenous Cushing\u2019s syndrome using a web-based questionnaire and validated patient-reported outcome measures"],"prefix":"10.1007","volume":"26","author":[{"given":"Gabrielle","family":"Page-Wilson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhagyashree","family":"Oak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Silber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janetricks","family":"Okeyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nancy","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"O\u2019Hara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Moloney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliza B.","family":"Geer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,4,19]]},"reference":[{"issue":"9996","key":"1314_CR1","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/S0140-6736(14)61375-1","volume":"386","author":"A Lacroix","year":"2015","unstructured":"Lacroix A et al (2015) Cushing\u2019s syndrome. Lancet 386(9996):913\u2013927","journal-title":"Lancet"},{"issue":"3","key":"1314_CR2","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1530\/EJE-11-1095","volume":"167","author":"RA Feelders","year":"2012","unstructured":"Feelders RA et al (2012) The burden of Cushing\u2019s disease: clinical and health-related quality of life aspects. Eur J Endocrinol 167(3):311\u2013326","journal-title":"Eur J Endocrinol"},{"key":"1314_CR3","unstructured":"Rubinstein G et al (2020) Time to diagnosis in Cushing\u2019s syndrome: a Meta-analysis based on 5367 patients.J Clin Endocrinol Metab, 105(3)"},{"issue":"8","key":"1314_CR4","doi-asserted-by":"publisher","first-page":"2807","DOI":"10.1210\/jc.2015-1818","volume":"100","author":"LK Nieman","year":"2015","unstructured":"Nieman LK et al (2015) Treatment of Cushing\u2019s syndrome: an endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 100(8):2807\u20132831","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"1314_CR5","first-page":"5325","volume":"104","author":"LHA Broersen","year":"2019","unstructured":"Broersen LHA et al (2019) Improvement but no normalization of quality of life and cognitive functioning after treatment of Cushing Syndrome. J Clin Endocrinol Metab 104(11):5325\u20135337","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"1314_CR6","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1016\/j.ando.2018.03.007","volume":"79","author":"SM Webb","year":"2018","unstructured":"Webb SM et al (2018) Quality of life in Cushing\u2019s disease: a long term issue? Ann Endocrinol (Paris) 79(3):132\u2013137","journal-title":"Ann Endocrinol (Paris)"},{"issue":"9","key":"1314_CR7","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1007\/s40265-019-01128-7","volume":"79","author":"JM Hinojosa-Amaya","year":"2019","unstructured":"Hinojosa-Amaya JM, Cuevas-Ramos D, Fleseriu M (2019) Medical Management of Cushing\u2019s syndrome: current and emerging treatments. Drugs 79(9):935\u2013956","journal-title":"Drugs"},{"issue":"6","key":"1314_CR8","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s11102-018-0897-z","volume":"21","author":"LHA Broersen","year":"2018","unstructured":"Broersen LHA et al (2018) Effectiveness of medical treatment for Cushing\u2019s syndrome: a systematic review and meta-analysis. Pituitary 21(6):631\u2013641","journal-title":"Pituitary"},{"key":"1314_CR9","doi-asserted-by":"publisher","first-page":"732240","DOI":"10.3389\/fendo.2021.732240","volume":"12","author":"J Sim\u00f5es Corr\u00eaa Galendi","year":"2021","unstructured":"Sim\u00f5es Corr\u00eaa Galendi J et al (2021) Effectiveness of Medical Treatment of Cushing\u2019s Disease: a systematic review and Meta-analysis. Front Endocrinol (Lausanne) 12:732240","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"4","key":"1314_CR10","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1210\/er.2013-1048","volume":"36","author":"R Pivonello","year":"2015","unstructured":"Pivonello R et al (2015) The treatment of Cushing\u2019s Disease. Endocr Rev 36(4):385\u2013486","journal-title":"Endocr Rev"},{"issue":"5","key":"1314_CR11","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1007\/s11102-015-0636-7","volume":"18","author":"CD Andela","year":"2015","unstructured":"Andela CD et al (2015) Quality of life (QoL) impairments in patients with a pituitary adenoma: a systematic review of QoL studies. Pituitary 18(5):752\u2013776","journal-title":"Pituitary"},{"issue":"2","key":"1314_CR12","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1111\/cen.13719","volume":"89","author":"W Ho","year":"2018","unstructured":"Ho W, Druce M (2018) Quality of life in patients with adrenal disease: a systematic review. Clin Endocrinol (Oxf) 89(2):119\u2013128","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"4","key":"1314_CR13","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1007\/s10143-019-01134-z","volume":"43","author":"M Pertichetti","year":"2020","unstructured":"Pertichetti M et al (2020) Pituitary adenomas and neuropsychological status: a systematic literature review. Neurosurg Rev 43(4):1065\u20131078","journal-title":"Neurosurg Rev"},{"key":"1314_CR14","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fnhum.2019.00086","volume":"13","author":"AWK Yeung","year":"2019","unstructured":"Yeung AWK, Wong NSM (2019) The historical roots of Visual Analog Scale in psychology as revealed by reference publication year spectroscopy. Front Hum Neurosci 13:86","journal-title":"Front Hum Neurosci"},{"issue":"5","key":"1314_CR15","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1002\/(SICI)1097-0142(19990301)85:5<1186::AID-CNCR24>3.0.CO;2-N","volume":"85","author":"TR Mendoza","year":"1999","unstructured":"Mendoza TR et al (1999) The rapid assessment of fatigue severity in cancer patients: use of the brief fatigue inventory. Cancer 85(5):1186\u20131196","journal-title":"Cancer"},{"issue":"6","key":"1314_CR16","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/sleep\/33.6.781","volume":"33","author":"DJ Buysse","year":"2010","unstructured":"Buysse DJ et al (2010) Development and validation of patient-reported outcome measures for sleep disturbance and sleep-related impairments. Sleep 33(6):781\u2013792","journal-title":"Sleep"},{"key":"1314_CR17","unstructured":"Measures H (2022) PROMIS: Intro to PROMIS. [cited 2022 11\/22\/22]; Available from: https:\/\/www.healthmeasures.net\/explore-measurement-systems\/promis"},{"issue":"3","key":"1314_CR18","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1177\/1073191111411667","volume":"18","author":"PA Pilkonis","year":"2011","unstructured":"Pilkonis PA et al (2011) Item banks for measuring emotional distress from the patient-reported outcomes Measurement Information System (PROMIS\u00ae): depression, anxiety, and anger. Assessment 18(3):263\u2013283","journal-title":"Assessment"},{"key":"1314_CR19","unstructured":"CDC, About Adult BMI (2022) [cited 2022 11\/22\/2022]; Available from: https:\/\/www.cdc.gov\/healthyweight\/assessing\/bmi\/adult_bmi\/index.html"},{"key":"1314_CR20","doi-asserted-by":"crossref","unstructured":"Page-Wilson G (2022) Economic and Health-Related Quality of Life Burden in Endogenous Cushing\u2019s syndrome: a systematic literature review abstract, in the Professional Society for Health Economics and Outcomes Research. United States","DOI":"10.1016\/j.jval.2022.04.1703"},{"issue":"1","key":"1314_CR21","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1186\/s13023-018-0958-4","volume":"13","author":"N Knoble","year":"2018","unstructured":"Knoble N et al (2018) Illustration of patient-reported outcome challenges and solutions in rare diseases: a systematic review in Cushing\u2019s syndrome. Orphanet J Rare Dis 13(1):228","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"1314_CR22","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1007\/s11102-015-0654-5","volume":"18","author":"MS Broder","year":"2015","unstructured":"Broder MS et al (2015) Incremental healthcare resource utilization and costs in US patients with Cushing\u2019s disease compared with diabetes mellitus and population controls. Pituitary 18(6):796\u2013802","journal-title":"Pituitary"},{"issue":"2","key":"1314_CR23","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s11102-015-0695-9","volume":"19","author":"T Burton","year":"2016","unstructured":"Burton T et al (2016) Algorithm development and the clinical and economic burden of Cushing\u2019s disease in a large US health plan database. Pituitary 19(2):167\u2013174","journal-title":"Pituitary"},{"issue":"11","key":"1314_CR24","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.1007\/s40618-020-01246-0","volume":"43","author":"A Lacroix","year":"2020","unstructured":"Lacroix A et al (2020) Long-acting pasireotide improves clinical signs and quality of life in Cushing\u2019s disease: results from a phase III study. J Endocrinol Invest 43(11):1613\u20131622","journal-title":"J Endocrinol Invest"},{"issue":"2","key":"1314_CR25","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1530\/EJE-18-0212","volume":"179","author":"A Osswald","year":"2018","unstructured":"Osswald A et al (2018) Surviving ectopic Cushing\u2019s syndrome: quality of life, cardiovascular and metabolic outcomes in comparison to Cushing\u2019s disease during long-term follow-up. Eur J Endocrinol 179(2):109\u2013116","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1314_CR26","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ando.2018.01.002","volume":"80","author":"P Sarkis","year":"2019","unstructured":"Sarkis P et al (2019) Bilateral adrenalectomy in Cushing\u2019s disease: altered long-term quality of life compared to other treatment options. Ann Endocrinol (Paris) 80(1):32\u201337","journal-title":"Ann Endocrinol (Paris)"},{"issue":"3","key":"1314_CR27","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1007\/s12020-018-1664-7","volume":"61","author":"M Vermalle","year":"2018","unstructured":"Vermalle M et al (2018) Lack of functional remission in Cushing\u2019s syndrome. Endocrine 61(3):518\u2013525","journal-title":"Endocrine"},{"key":"1314_CR28","doi-asserted-by":"crossref","unstructured":"Zarino B et al (2019) Cushing\u2019s disease: a prospective case-control study of health-related quality of life and cognitive status before and after surgery.J Neurosurg, : p.1\u201311","DOI":"10.3171\/2019.8.JNS19930"},{"issue":"12","key":"1314_CR29","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1016\/S2213-8587(21)00235-7","volume":"9","author":"M Fleseriu","year":"2021","unstructured":"Fleseriu M et al (2021) Consensus on diagnosis and management of Cushing\u2019s disease: a guideline update. Lancet Diabetes Endocrinol 9(12):847\u2013875","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"2","key":"1314_CR30","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1530\/eje.1.01953","volume":"153","author":"A Bhattacharyya","year":"2005","unstructured":"Bhattacharyya A et al (2005) Steroid withdrawal syndrome after successful treatment of Cushing\u2019s syndrome: a reminder. Eur J Endocrinol 153(2):207\u2013210","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"1314_CR31","doi-asserted-by":"publisher","first-page":"R1","DOI":"10.1530\/EJE-14-1101","volume":"173","author":"CD Andela","year":"2015","unstructured":"Andela CD et al (2015) MECHANISMS IN ENDOCRINOLOGY: Cushing\u2019s syndrome causes irreversible effects on the human brain: a systematic review of structural and functional magnetic resonance imaging studies. Eur J Endocrinol 173(1):R1\u201314","journal-title":"Eur J Endocrinol"},{"issue":"1\u20133","key":"1314_CR32","first-page":"30","volume":"17","author":"TY Lin","year":"2020","unstructured":"Lin TY, Hanna J, Ishak WW (2020) Psychiatric symptoms in Cushing\u2019s syndrome: a systematic review. Innov Clin Neurosci 17(1\u20133):30\u201335","journal-title":"Innov Clin Neurosci"},{"issue":"10","key":"1314_CR33","doi-asserted-by":"publisher","first-page":"4563","DOI":"10.1210\/jc.2019-00749","volume":"104","author":"KE Frimodt-M\u00f8ller","year":"2019","unstructured":"Frimodt-M\u00f8ller KE et al (2019) Hippocampal volume, cognitive functions, Depression, anxiety, and quality of life in patients with Cushing Syndrome. J Clin Endocrinol Metab 104(10):4563\u20134577","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"1314_CR34","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.jval.2017.09.009","volume":"21","author":"PG Kluetz","year":"2018","unstructured":"Kluetz PG et al (2018) Informing the tolerability of Cancer Treatments using patient-reported outcome measures: Summary of an FDA and critical path Institute Workshop. Value Health 21(6):742\u2013747","journal-title":"Value Health"},{"issue":"1","key":"1314_CR35","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1007\/s11102-020-01103-6","volume":"24","author":"EB Geer","year":"2021","unstructured":"Geer EB et al (2021) Levoketoconazole improves clinical signs and symptoms and patient-reported outcomes in patients with Cushing\u2019s syndrome. Pituitary 24(1):104\u2013115","journal-title":"Pituitary"},{"key":"1314_CR36","unstructured":"Statistics CNCfH (2022) Ambulatory Care Use and Physician office visits. [cited 2022 11\/22\/2022]; Available from: https:\/\/www.cdc.gov\/nchs\/fastats\/physician-visits.htm"},{"issue":"1","key":"1314_CR37","doi-asserted-by":"publisher","first-page":"77","DOI":"10.4158\/EP14126.OR","volume":"21","author":"MS Broder","year":"2015","unstructured":"Broder MS et al (2015) Burden of illness, annual healthcare utilization, and costs associated with commercially insured patients with cushing disease in the United States. Endocr Pract 21(1):77\u201386","journal-title":"Endocr Pract"},{"key":"1314_CR38","unstructured":"CDC. MMWR (2022) [cited 2022 11\/22\/2022]; Available from: https:\/\/www.cdc.gov\/mmwr\/preview\/mmwrhtml\/mm5830a5.htm"},{"issue":"6","key":"1314_CR39","doi-asserted-by":"publisher","first-page":"1750","DOI":"10.1210\/clinem\/dgab079","volume":"106","author":"D Bengtsson","year":"2021","unstructured":"Bengtsson D et al (2021) Psychotropic drugs in patients with Cushing\u2019s Disease before diagnosis and at Long-Term Follow-Up: a Nationwide Study. J Clin Endocrinol Metab 106(6):1750\u20131760","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Pituitary"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01314-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11102-023-01314-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11102-023-01314-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T07:15:36Z","timestamp":1690960536000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11102-023-01314-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,19]]},"references-count":39,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["1314"],"URL":"https:\/\/doi.org\/10.1007\/s11102-023-01314-7","relation":{},"ISSN":["1386-341X","1573-7403"],"issn-type":[{"value":"1386-341X","type":"print"},{"value":"1573-7403","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,19]]},"assertion":[{"value":"30 March 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 April 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This was an observational study conducted in accordance with the 1964 Declaration of Helsinki and its later amendments. As this was not a randomized clinical trial, the study was not registered as such. The ADVARRA Institutional Review Board (Columbia, MD; ) has granted the study exemption from IRB oversight using the Department of Health and Human Services regulations found at 45 CFR 46.104(d)(2). The IRB also completed the necessary additional limited review considerations as set forth under the Revised Common Rule, 45 CFR 46.104(d).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Informed consent was obtained from all participants included in the study during the screening process and this was required to successfully enroll into the study. Participants were able to exit the study at any time or refuse to answer any questions.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Study participants consented to the publication of their data anonymously on an aggregate basis.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}]}}